Comparing Grail (NASDAQ:GRAL) & Sera Prognostics (NASDAQ:SERA)

Grail (NASDAQ:GRAL) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Earnings and Valuation

This table compares Grail and Sera Prognostics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grail	$125.60 million	11.53	N/A	N/A	N/A
Sera Prognostics	$94,000.00	1,512.55	-$36.24 million	($0.99)	-4.25

Grail has higher revenue and earnings than Sera Prognostics.

Analyst Ratings

This is a summary of current ratings and recommmendations for Grail and Sera Prognostics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grail	0	3	0	0	2.00
Sera Prognostics	0	0	1	0	3.00

Grail presently has a consensus price target of $16.00, indicating a potential downside of 62.89%. Given Grail’s higher possible upside, equities analysts clearly believe Grail is more favorable than Sera Prognostics.

Profitability

This table compares Grail and Sera Prognostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grail	N/A	N/A	N/A
Sera Prognostics	N/A	-51.73%	-36.94%

Insider & Institutional Ownership

54.6% of Sera Prognostics shares are owned by institutional investors. 15.8% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Sera Prognostics beats Grail on 5 of the 9 factors compared between the two stocks.

About Grail

GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.